# Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

> **NCT05241535** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** MT-7117
- **DRUG:** moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05241535
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-12
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241535, "Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05241535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*